NF1 and neoplasm: However, levels of phosphorylated MEK and ERK would be difficult both to obtain and quantify, and therefore our data identifying NF1 as a biomarker that predicts both patient outcomes and responsiveness of neuroblastoma tumor cells to MEK inhibition supports a potential role for readily available genetic testing for NF1 mutations and deletions in tumor samples.